Literature DB >> 24643999

Genetic association of gastric cancer with miRNA clusters including the cancer-related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC-EURGAST study.

Yolanda Espinosa-Parrilla1, Xavier Muñoz, Catalina Bonet, Nadia Garcia, Adoración Venceslá, Nikos Yiannakouris, Alessio Naccarati, Sabina Sieri, Salvatore Panico, José M Huerta, Aurelio Barricarte, Virginia Menéndez, Emilio Sánchez-Cantalejo, Miren Dorronsoro, Paul Brennan, Talita Duarte-Salles, H B As Bueno-de-Mesquita, Elisabete Weiderpass, Eiliv Lund, Françoise Clavel-Chapelon, Marie-Christine Boutron-Ruault, Antoine Racine, Mattijs E Numans, Rosario Tumino, Federico Canzian, Daniele Campa, Malin Sund, Mattias Johansson, Bodil Ohlsson, Björn Lindkvist, Kim Overvad, Anne Tjønneland, Domenico Palli, Ruth C Travis, Kay-Tee Khaw, Nick Wareham, Heiner Boeing, Gabriella Nesi, Elio Riboli, Carlos A Gonzalez, Núria Sala.   

Abstract

MicroRNAs (miRNAs) are post-transcriptional gene regulators involved in a wide range of biological processes including tumorigenesis. Deregulation of miRNA pathways has been associated with cancer but the contribution of their genetic variability to this disorder is poorly known. We analyzed the genetic association of gastric cancer (GC) and its anatomical and histological subtypes, with 133 single-nucleotide polymorphisms (SNPs) tagging 15 isolated miRNAs and 24 miRNA clusters potentially involved in cancer, in 365 GC cases and 1,284 matched controls within the European Prospective Investigation into Cancer and Nutrition cohort. Various SNPs were associated with GC under the log-additive model. Furthermore, several of these miRNAs passed the gene-based permutation test when analyzed according to GC subtypes: three tagSNPs of the miR-29a/miR-29b-1 cluster were associated with diffuse subtype (minimum p-value = 1.7 × 10(-4) ; odds ratio, OR = 1.72; 95% confidence interval, CI = 1.30-2.28), two tagSNPs of the miR-25/miR-93/miR-106b cluster were associated with cardia GC (minimum p-value = 5.38 × 10(-3) ; OR = 0.56, 95% CI = 0.37-0.86) and one tagSNP of the miR-363/miR-92a-2/miR-19b-2/miR-20b/miR-18b/miR-106a cluster was associated with noncardia GC (minimum p-value = 5.40 × 10(-3) ; OR = 1.41, 95% CI = 1.12-1.78). Some functionally validated target genes of these miRNAs are implicated in cancer-related processes such as methylation (DNMT3A, DNMT3B), cell cycle (E2F1, CDKN1A, CDKN1C), apoptosis (BCL2L11, MCL1), angiogenesis (VEGFA) and progression (PIK3R1, MYCN). Furthermore, we identified genetic interactions between variants tagging these miRNAs and variants in their validated target genes. Deregulation of the expression of these miRNAs in GC also supports our findings, altogether suggesting for the fist time that genetic variation in MIR29, MIR25, MIR93 and MIR106b may have a critical role in genetic susceptibility to GC and could contribute to the molecular mechanisms of gastric carcinogenesis.
© 2014 UICC.

Entities:  

Keywords:  cancer genetic susceptibility; gastric adenocarcinoma; miRNA; miRNA cluster; polymorphisms; posttranscriptional regulation; prospective cohort; tagSNP

Mesh:

Substances:

Year:  2014        PMID: 24643999     DOI: 10.1002/ijc.28850

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Analysis of plasma MicroRNAs to identifying early diagnostic molecule for gastric cancer.

Authors:  Zi-Zhen Zhang; Chao-Jie Wang; Li Niu; Jia Xu; Ming Wang; Hui Cao; Bo Hu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 2.  MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis of gastric cancer.

Authors:  C Jiang; X Chen; M Alattar; J Wei; H Liu
Journal:  Cancer Gene Ther       Date:  2015-05-22       Impact factor: 5.987

3.  aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.

Authors:  Yoshihiko Fujita; Masataka Taguri; Kentaro Yamazaki; Junji Tsurutani; Kazuko Sakai; Takahiro Tsushima; Michitaka Nagase; Hiroshi Tamagawa; Shinya Ueda; Takao Tamura; Yasushi Tsuji; Kohei Murata; Koichi Taira; Tadamichi Denda; Toshikazu Moriwaki; Sadao Funai; Takako Eguchi Nakajima; Kei Muro; Akihito Tsuji; Motoki Yoshida; Koichi Suyama; Takuya Kurimoto; Naotoshi Sugimoto; Eishi Baba; Nobuhiko Seki; Mikio Sato; Takaya Shimura; Narikazu Boku; Ichinosuke Hyodo; Takeharu Yamanaka; Kazuto Nishio
Journal:  Oncologist       Date:  2018-11-13

Review 4.  miR-106b as an emerging therapeutic target in cancer.

Authors:  Surendra Kumar Sagar
Journal:  Genes Dis       Date:  2021-02-12

5.  Exosomal miR-106a derived from gastric cancer promotes peritoneal metastasis via direct regulation of Smad7.

Authors:  Meng Zhu; Ning Zhang; Shuixiang He; Xinlan Lu
Journal:  Cell Cycle       Date:  2020-04-08       Impact factor: 4.534

6.  An Antagomir to MicroRNA-106b-5p Ameliorates Cerebral Ischemia and Reperfusion Injury in Rats Via Inhibiting Apoptosis and Oxidative Stress.

Authors:  Pengfei Li; Meihong Shen; Feng Gao; Jinping Wu; Jiahui Zhang; Fengmeng Teng; Chunbing Zhang
Journal:  Mol Neurobiol       Date:  2016-03-29       Impact factor: 5.590

7.  A cross-cancer differential co-expression network reveals microRNA-regulated oncogenic functional modules.

Authors:  Chen-Ching Lin; Ramkrishna Mitra; Feixiong Cheng; Zhongming Zhao
Journal:  Mol Biosyst       Date:  2015-12

8.  Function analysis of rs9589207 polymorphism in miR-92a in gastric cancer.

Authors:  Changming Liu; Ying Zhang; Haijun Chen; Lixing Jiang; Daping Xiao
Journal:  Tumour Biol       Date:  2015-10-25

9.  MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF.

Authors:  Zhenlei Wang; Bin Ma; Xiaopin Ji; Yang Deng; Tao Zhang; Xiaojian Zhang; Haoji Gao; Hanxing Sun; Haoxuan Wu; Xianze Chen; Ren Zhao
Journal:  Cancer Cell Int       Date:  2015-04-15       Impact factor: 5.722

10.  Exploring microRNA target genes and identifying hub genes in bladder cancer based on bioinformatic analysis.

Authors:  Hongjian Wu; Wubing Jiang; Guanghua Ji; Rong Xu; Gaobo Zhou; Hongyuan Yu
Journal:  BMC Urol       Date:  2021-06-10       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.